COMPARISON OF SAFETY OF LATANOPROST WITH PRESERVATIVE BENZALKONIUM CHLORIDE (BAK) VERSUS BAK-FREE TRAVOPROST IN PRIMARY OPEN-ANGLE GLAUCOMA
DOI:
https://doi.org/10.22159/ajpcr.2022.v15i7.44829Keywords:
Primary open-angle glaucoma, Latanoprost, Travoprost, Benzalkonium chloride, Schirmer test, Tear break-up time, Ocular surface disease indexAbstract
Objective: The objective of this study was to compare the safety of BAK-preserved latanoprost versus travoprost BAK-free ophthalmic solution in the primary open-angle glaucoma (POAG).
Methods: Prospective, open-labeled, and randomized comparative study conducted in tertiary care hospital. Forty patients were enrolled and divided into 20 patients in each group: Group A topical latanoprost (0.005%) with BAK and Group B topical BAK-free travoprost (0.004%). Safety assessment was done by following parameters – Schrimer test (ST), tear break-up time (TBUT), and ocular surface disease index (OSDI).
Results: ST and TBUT were calculated at baseline, 1 month, 2 months, 3 months, and 4 months and OSDI scores were calculated at baseline, 2 months and 4 months. Group A and B were compared using ST, TBUT, and OSDI scores. Group B showed statistically significant results (p<0.05).
Conclusion: Topical BAK-free travoprost is more tolerable than BAK-preserved latanoprostin POAG.
Downloads
References
Khurana AK. Comprehensive Opthalmology. 6th ed. Rohtak: New International Pvt. Ltd.; 2015. p. 214-215.
Allison K, Patel D, Alabi O. Epidemiology of glaucoma: The past, present, and predictions for the future. Cureus 2020;12:e11686. doi: 10.7759/cureus.11686, PMID 33391921
Senjam SS. Glaucoma blindness-a rapidly emerging non-communicable ocular disease in India: Addressing the issue with advocacy. J Fam Med Prim Care 2020;9:2200-6. doi: 10.4103/jfmpc. jfmpc_111_20, PMID 32754474
Bagnis A, Papadia M, Scotto R, Traverso CE. Antiglaucoma drugs: The role of preservative-free formulations. Saudi J Ophthalmol 2011;25:389-94. doi: 10.1016/j.sjopt.2011.08.004, PMID 23960953
Kumar G, Chaurasia RC, Singh SP. Efficacy and adverse effects of topical latanoprost with respect to preservative in patients of POAG. J Clin Diagn Res 2018;12:FC06-9. doi: 10.7860/JCDR/2018/29284.11891
Jayanthi CR, Divyasree RN, Sujitha BL. Efficacy and safety of topical BAK-free travoprost 0.004% versus BAK-preserved travoprost 0.004% in the treatment of primary open angle glaucoma: A comparative study at a tertiary care hospital. Int J Basic Clin Pharmacol 2017;6:2199-205. doi: 10.18203/2319-2003.ijbcp20173744
Kurna SA, Acikgoz S, Altun A, Ozbay N, Sengor T, Olcaysu OO. The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: A prospective study. J Ophthalmol 2014;2014:460483.
Dibajnia P, Mohammadinia M, Moghadasin M, Amiri MA. Tear film break-up time in bipolar disorder. Iran J Psychiatry 2012;7:191-3. PMID 23408791
Ozcura F, Aydin S, Helvaci MR. Ocular surface disease index for the diagnosis of dry eye syndrome. Ocul Immunol Inflamm 2007;15:389-93. doi: 10.1080/09273940701486803, PMID 17972223
Chhabra H, Gupta A, Singh G. A comparative study of benzalkonium chloride-free latanoprost versus benzalkonium chloride-preserved latanoprost on ocular surface health in patients of primary open angle glaucoma. Int J Basic Clin Pharmacol 2017;6:1110-4. doi: 10.18203/2319-2003.ijbcp20171660
El Hajj Moussa WG, Farhat RG, Nehme JC, Sahyoun MA, Schakal AR, Jalkh AE, et al. Comparison of efficacy and ocular surface disease index score between bimatoprost, latanoprost, travoprost, and tafluprost in glaucoma patients. J Ophthalmol 2018;2018:1319628. doi: 10.1155/2018/1319628, PMID 29707390
Lopes JF, Hubatsch DA, Amaris P. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: An open-label study. BMC Ophthalmol 2015;15:166. doi: 10.1186/s12886-015-0151-7, PMID 26563363
Published
How to Cite
Issue
Section
Copyright (c) 2022 POOJA JUNEJA
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
